{"page":{"totalFilteredElements":90},"studies":[{"active":true,"description":"<p style=\"line-height:normal;margin-top:0pt;margin-bottom:0pt;margin-left:0in;\">A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the \nEfficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP \nChemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma<br /></p>","eudractNumber":"2023-510178-15","id":10012,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-23T12:23:27+02:00","shortTitle":"CA073-1020 GOLSEEK-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"CAELUM Cardiac Amyloid Reaching for Extended Survival&#160;A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia&#160;Treatment-Na&#239;ve Patients with Mayo Stage IIIb AL Amyloidosis<br />","eudractNumber":"2019-004254-28","id":6946,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04504825","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-26T11:02:10+02:00","shortTitle":"CAEL101-301","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p align=\"left\" class=\"Text\">Long Term\nFollow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (PAVO)</p>","eudractNumber":"2014-001673-14","id":1805,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02445222","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2016-05-11T11:16:30+02:00","shortTitle":"CAR-T Long Term Follow Up (LTFU) Study, CCTL019A2205B (PAVO)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"CARMAN: Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance following CAR-T-cell treatment (Arm A) as compared to standard of care induction and maintenance (Arm B)","eudractNumber":"2022-502405-15-00","id":7711,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-08-05T08:41:24+02:00","shortTitle":"CARMAN - GLA 2022-11","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and \nDexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab,&#160; Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell \nTransplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are \nTransplant Eligible","eudractNumber":"2021-003284-10","id":9102,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05257083","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T12:31:22+02:00","shortTitle":"CARTITUDE-6, EMN28/68284528MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus<br />Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in<br />Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small<br />Lymphocytic Lymphoma","eudractNumber":"2024-517131-52-00","id":11276,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT06943872","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-10-31T08:53:02+01:00","shortTitle":"CELESTIAL-RR CLL (BGB-11417-303)","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Langzeitnachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/NK-LGL, HCL und Richter Transformation","eudractNumber":null,"id":1659,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02863692","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-07-01T10:53:05+02:00","shortTitle":"CLL-Registry [DCLLSG Register]","therapeutical":false,"therapyLines":[]},{"active":true,"description":"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUK&#196;MIE (CLL): CLL-16 STUDIE DER DCLLSG","eudractNumber":"2020-004360-26","id":8660,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT05197192","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-25T14:28:21+02:00","shortTitle":"CLL16","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \nadjustment of treatment duration to improve outcomes","eudractNumber":"2023-510294-34","id":11270,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-11T11:42:59+02:00","shortTitle":"CLL18 / MOIRAI-TRIAL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A prospective observational trial to assess treatment sequences and factors that impact<br />overall survival in patients with chronic lymphocytic leukaemia (CLL) treated within first-line<br />studies of the GCLLSG","eudractNumber":null,"id":12152,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06792994","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-06-22T10:53:24+02:00","shortTitle":"CLL2000","therapeutical":false,"therapyLines":[]}]}